<DOC>
	<DOCNO>NCT00842361</DOCNO>
	<brief_summary>This trial conduct Japan . The aim clinical trial investigate safety ( emphasis hypoglycaemia ) switch long-acting insulin analogue/intermediate-acting insulin pre-mixed insulin/pre-mixed insulin analogue twice daily regimen NN5401 ( SIAC , insulin degludec/insulin aspart ) twice daily regimen subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Comparison NN5401 Versus Biphasic Insulin Aspart 30 Twice Daily Regimen Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects type 2 diabetes mellitus Current treatment use longacting insulin analogue/intermediateacting insulin preparation ( except insulin glargine ) premixed insulin/insulin analogue preparation ( except Mix30 ) twice daily regimen least 12 week , stable insulin dose last 4 week ( brand insulin preparation dose regimen change precede 12 week ) HbA1c 10.0 % Body Mass Index ( BMI ) &lt; 30.0 kg/m^2 Known hypoglycaemia unawareness recurrent major hypoglycaemia Current treatment total insulin dose 100 U IU/day Current treatment expect start treatment systemic corticosteroid Treatment oral antidiabetic drug ( OADs : include alphaglucosidase inhibitor insulin sensitizer [ thiazolidinedione : TZD ] ) within last 12 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>